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Psoriasiform drug eruptionAbstract Levetiracetam (LEV) is an established second generation anti-epileptic drug and LEV
associated severe cutaneous reactions are rare. Here we report the case of psoriasiform drug erup-
tion in a patient with newly diagnosed epilepsy who had been treated with levetiracetam. To our
knowledge this is the ﬁrst report of a patient with a psoriasiform eruption that appeared after
the administration of LEV.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Levetiracetam (LEV) is an established second generation anti-
epileptic drug which is used as monotherapy in patients with
new diagnosed partial onset or generalized tonic-clonic
(GTC) seizures, adjunctive therapy in patients with refractory
partial onset seizures and idiopathic generalized epilepsy with
myoclonic or GTC seizures. LEV associated severe cutaneousreactions are rare (Lyseng-Williamson, 2011). Here we report
the case of psoriasiform drug eruption in a patient with newly
diagnosed epilepsy who had been treated with levetiracetam.
To our knowledge this is the ﬁrst report of a patient with a
psoriasiform eruption that appeared after the administration
of LEV.
2. Case report
In April 2013, a right handed 35 year old woman presented to
our neurology department with generalized tonic-clonic con-
vulsions 2 times a week. Both seizures lasted approximately
for 2 min. This was her ﬁrst seizure and there was no history
of febrile seizure, head trauma, cerebrovascular disease, central
nervous system infection and family history of epilepsy.
Neurological examination ﬁndings were normal. Laboratory
ﬁndings were normal except eosinophilia and brain magnetic
resonance imaging examination result was normal. The patient
underwent electroencephalography (EEG) monitoring and two
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frontal lobes of both hemispheres were noted.
She was diagnosed with epilepsy and started treatment with
LEV 500 mg per day. The dose of LEV was gradually
increased to 1000 mg per day. 10 days after antiepileptic ther-
apy, the erythematous skin lesions developed. She had not tak-
en any other medications and she had no personal or family
history of psoriasis. Physical examination revealed that erythe-
matous plaques with scales were presented on both knees and
elbows. Her scalp, nails and palmar plantar regions were not
affected. She had no fever and laboratory ﬁndings were normal
except eosinophilia. Histological examination of the skin biop-
sy specimen taken from a lesion on the knee, revealed irregular
acanthosis of epidermis, oedema in papillary dermis, dilated
capillary congestion nearby basal membrane and perivascular
inﬁltrate composed of mononuclear cells in superﬁcial reticular
dermis as shown in ﬁgure. The patient was diagnosed with pso-
riasiform drug eruption due to LEV. So LEV therapy was
stopped and carbamazepine 400 mg per day was initiated.
The skin eruptions began to disappear within few weeks after
discontinuing LEV therapy. No further recurrence of skin
lesions and epileptic seizures was observed in her follow up
(see Fig. 1)
3. Discussion
Psoriasiform drug eruptions simulating psoriasis clinically
and/or histologically can be induced by several drugs such as
beta blockers, lithium, antimalarial drugs, antibiotics, nonster-
oidal anti-inﬂammatory drugs, angiotensin-converting enzyme
inhibitors, interferons, terbinaﬁne, benzodiazepines (Kim and
Del Rosso, 2010; Sehgal et al., 2008). Although the histopatho-
logical features are similar to psoriasis, perivascular and inter-
stitial inﬁltration of eosinophils in the upper dermis is more
frequent in psoriasiform drug eruption (Justiniano et al.,
2008). Psoriasiform drug eruption is divided into 2 categories.
The ﬁrst category is exacerbation of pre-existing psoriasis andFigure 1 Histological features of the skin biopsy from the knee
reveals irregular acanthosis of epidermis, oedema in papillary
dermis, dilated capillary congestion nearby basal membrane and
perivascular inﬁltrate composed of mononuclear cells in superﬁcial
reticular dermis. (Haematoxylin-eosin, original magniﬁcation
100·).development of psoriatic lesions on uninvolved skin in patients
with psoriasis. The second category includes precipitation of
psoriasis in patients with no predisposed individuals and
family history of psoriasis (Yamamoto et al., 2008).
Skin reaction is a common side effect of antiepileptic drugs
(AED) Alvestad et al., 2007; Wang et al., 2010. The most com-
mon type of adverse reactions is mild maculopapular rashes
which disappeared within few days after discontinuation of the
drug (Mockenhaupt et al., 2005; Chadwick et al., 1984). More
serious AED-related adverse reactions can also occur as toxic
epidermal necrolysis (TEN), Stevens–Johnson syndrome,
Drug Reaction with Eosinophilia and Systemic Symptoms
(DRESS), anticonvulsant hypersensitivity syndrome and
angioedema (Mockenhaupt et al., 2005; Alkhotani and
McLachlan, 2012; Pereira de Silva et al., 2011; Newell et al.,
2009).
Several factors are associated with the development of skin
reactions. Ageing and female gender seem to increase the risk
of skin rashes (Blaszczyk et al., 2013). The pathogenesis of
cutaneous adverse reactions is related to both metabolic and
immunological mechanisms that can be caused by hapten
hypothesis of drug hypersensitivity. Reactive metabolites of
the drug occur as a result of imbalance between metabolic
bio activation and detoxiﬁcation. These metabolites may bind
irreversibly to endogenous proteins and the interaction of T-
cell lymphocyte clones and both drug and these drug modiﬁed
proteins can cause delayed immune responses (Alvestad et al.,
2007).
As noted in previous studies, AEDs with aromatic ring
structures such as phenytoin and carbamazepine had relatively
high incidences of cutaneous adverse reactions (Handoko
et al., 2008). Sodium valproate, LEV, vigabatrin and topira-
mate are rarely associated with these reactions. LEV which is
an established second generation antiepileptic drug, has a nov-
el structure and is associated with rapid, complete absorption
and high oral bioavailability. Renal clearance is the major way
of elimination. Previous studies have reported that the inci-
dence of LEV related adverse events was similar to placebo
group. Severe hypersensitivity cutaneous reactions were not
associated with LEV (Lyseng-Williamson, 2011).
Here we report a psoriasiform drug eruption related to leve-
tiracetam. To our knowledge, this is the ﬁrst case report of this
type of cutaneous adverse reaction due to levetiracetam. So
according to this, we must be prepared to any side effect of
well tolerated and safely used antiepileptic drugs.Source(s) of support
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